OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting

Presentation to highlight the scientific characteristics of the novel first-in-class anti Globo H antibody-drug conjugate (ADC), OBI-999. TAIPEI, Taiwan, Sept 14, 2020/PRNewswire/OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held for OBI-999 […]